Tempus Acquires Personalis for $1.5 Billion to Expand MRD Capabilities — Personalis, Inc.

Event summary

Tempus AI to acquire Personalis for $1.5 billion, integrating tumor-informed MRD technology into its precision oncology platform.
Personalis shareholders receive $16.25 per share, a 6% premium over the closing price and 28% premium over 30-day VWAP.
Transaction expected to close in late 2026 or early 2027, subject to shareholder and regulatory approvals.
Personalis reported $22.4 million in Q2 revenue with a 33% increase in test volumes quarter-over-quarter.

The big picture

Tempus’ acquisition of Personalis strengthens its position in the precision oncology market by adding highly sensitive MRD technology, crucial for long-term cancer monitoring. The deal reflects growing demand for AI-driven diagnostic tools as more patients live longer post-diagnosis. With Medicare coverage expanding, Tempus aims to capture a rapidly growing segment of the cancer care market.

What we're watching

Integration Challenges: How Tempus will integrate Personalis’ MRD technology into its existing AI-enabled precision oncology platform.
Regulatory Approvals: Whether the transaction receives necessary regulatory approvals and shareholder votes by late 2026 or early 2027.
Market Expansion: The pace at which Tempus can expand access to longitudinal cancer monitoring with Personalis’ ultrasensitive MRD tests.